Exelixis (EXEL) 30-day volatility at 106 compared to 60 from a month ago
Exelixis (NASDAQ: EXEL) is recently down 17% on cabozantinib and Opdivo data concerns. 30-day call option implied volatility of 106 compares to volatility of 60 from a month ago.